Evidence map›Paper›PMID 31470791›Full record

ReviewThe journal of headache and pain2019

Current and emerging evidence-based treatment options in chronic migraine: a narrative review.

Elio Clemente Agostoni, Piero Barbanti, Paolo Calabresi, Bruno Colombo, Pietro Cortelli, Fabio Frediani, Pietrangelo Geppetti, Licia Grazzi, Massimo Leone, Paolo Martelletti and 6 more

2 registry-linked trialsOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The journal of headache and pain, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 68 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 8 pooled it
16.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05646160 naunknown statusnot on this map

Effects of Myofascial Trigger Points Therapy in Migraine.

TypeinterventionalSponsorJózef Piłsudski University of Physical EducationRan2018 to 2023Enrolled100ConditionsMigraine, Pain, Shoulder, Trapezius Muscle Strain Left, Trapezius Muscle Strain RightArmsIschemic Compression of Myofascial Trigger Points (IC-MTRPs)
NCT06267664 unknown statusnot on this mapstarted 2023, after this paper: background citation

Real-world Effectiveness and Tolerability of Triptans-Ditans-Gepants (TRIDIGEP): an International Prospective Multicentric Cohort Study

Typeobservational_patient_registrySponsorHospital Clínico Universitario de ValladolidRan2023 to 2024Enrolled1,500ConditionsMigraine, Migraine Disorders, Migraine With Aura, Headache DisordersArmsPatients with migraine treated with triptans, Lasmiditan or Gepants
3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 8 syntheses or guidelines pooled it, 177 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Selective loss and transcriptional reprogramming of Nox4The journal of headache and pain · 2025
    Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 1 country.

Elio Clemente AgostoniS.C. Neurologia e Stroke Unit ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Piero BarbantiHeadache and Pain Unit, Department of Neurological, Motor and Sensorial Sciences, IRCCS San Raffaele Pisana, Rome, Italy. piero.barbanti@sanraffaele.it.ORCID http://orcid.org/0000-0002-5670-3755
Paolo CalabresiNeurologic Clinic, Ospedale Santa Maria della, Perugia, Italy.
Bruno ColomboDipartimento di Neurologia, Università Vita-Salute, Ospedale San Raffaele, Milan, Italy.
Pietro CortelliIRCCS- Istituto di Scienze Neurologiche di Bologna, Bologna, Italy.
Fabio FredianiHeadache Centre, UOC Neurologia e Stroke Unit, P.O. San Carlo Borromeo, ASST Santi Paolo e Carlo, Milan, Italy.
Pietrangelo GeppettiDepartment of Health Sciences, Section of Clinical Pharmacology and Headache Center, University of Florence, Florence, Italy.
Licia GrazziFondazione IRCCS Istituto Neurologico "C.Besta", Milan, Italy.
Massimo LeoneFondazione IRCCS Istituto Neurologico "C.Besta", Milan, Italy.
Paolo MartellettiDepartment of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
Luigi Alberto PiniHeadache Center, Department of Biomedical, Metabolic and Neuro Science, University of Modena and Reggio Emilia, Modena, Italy.
Maria Pia PrudenzanoHeadache Center, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy.
Paola SarchielliHeadache Center, Neurologic Clinic, Ospedale Santa Maria della Misericordia, Perugia, Italy.
Gioacchino TedeschiHeadache Center Department of Medical, Surgical, Neurological, Metabolic, and Aging Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Antonio RussoHeadache Center Department of Medical, Surgical, Neurological, Metabolic, and Aging Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Italian chronic migraine group
Fondazione IRCCS Istituto Neurologico Carlo Besta · ITUniversity of Campania "Luigi Vanvitelli" · ITOspedale San Carlo · ITOspedale Santa Maria · ITUniversity of Modena and Reggio Emilia · ITVita-Salute San Raffaele University · ITAzienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · ITInstitute of Neurological Sciences · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic migraine is a disabling condition that is currently underdiagnosed and undertreated. In this narrative review, we discuss the future of chronic migraine management in relation to recent progress in evidence-based pharmacological treatment.

findingsPatients with chronic migraine require prophylactic therapy to reduce the frequency of migraine attacks, but the only currently available evidence-based prophylactic treatment options for chronic migraine are topiramate and onabotulinumtoxinA. Improved prophylactic therapy is needed to reduce the high burden of chronic migraine in Italy. Monoclonal antibodies that target the calcitonin gene-related peptide (CGRP) pathway of migraine pathogenesis have been specifically developed for the prophylactic treatment of chronic migraine. These anti-CGRP/R monoclonal antibodies have demonstrated good efficacy and excellent tolerability in phase II and III clinical trials, and offer new hope to patients who are currently not taking any prophylactic therapy or not benefitting from their current treatment.

conclusionsTreatment of chronic migraine is a dynamic and rapidly advancing area of research. New developments in this field have the potential to improve the diagnosis and provide more individualised treatments for this condition. Establishing a culture of prevention is essential for reducing the personal, social and economic burden of chronic migraine.

Indexed as

Antibodies, MonoclonalBotulinum Toxins, Type AChronic DiseaseHumansMigraine DisordersPersons with DisabilitiesRandomized Controlled Trials as TopicTopiramateAntibodies, MonoclonalBotulinum Toxins, Type ATopiramateAnti-CGRP monoclonal antibodiesChronic migraineFremanezumabonabotulinumtoxinAProphylaxisTopiramate

Identifiers

PMID31470791
PMCPMC6734211
OpenAlexW2970706487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.